Searched for
MANKIND PHARMA LISTING PRICE
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 26%On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...
SpaceX shares open at $150 in Nasdaq debutSpaceX shares indicated to open at $150 in Nasdaq debut vs IPO price of $135 per share.
GenXAI Analytics shares list at 20% discount to IPO price on NSE SME platformGenXAI Analytics shares listed on the NSE SME platform at a significant discount. The stock opened at Rs 92.8, below its IPO price of Rs 11...
PL Capital cuts Nifty target to 26,449, lists 16 high conviction stock picksAmidst global market turmoil from the Iran-US war and El Nino, PL Capital lowered its Nifty 50 target to 26,449. The brokerage anticipates ...
'Not a great environment for Indian market': Harsha Upadhyaya on Iran-US tensions, IT outlook, pharma bet, and where to be cautiousGlobal challenges are impacting Indian stocks. West Asian tensions and rising US inflation create headwinds. Tech sector shifts also affect...
India likely past peak outflows, AI gap its advantage, Lighthouse Canton saysDomestic benchmarks Nifty 50 and Sensex are down about 11% and 13% so far in 2026, respectively, after fears of AI-led disruption tanked th...
Hexagon Nutrition shares list at 7% premium over IPO price on boursesHexagon Nutrition debuted at a premium of up to 7.2% over its IPO price, in line with grey market expectations. The Rs 138.9 crore issue wa...
Market Trading Guide: Allied Blenders among 2 stock recommendations for FridayDomestic markets recovered modestly on easing oil prices and selective buying in banking and pharma stocks. Analysts have recommended Allie...
Sebi proposes common price-band mechanism for stocks listed on multiple exchangesSebi has proposed a new mechanism to harmonize stock price bands and pre-open auction prices across exchanges. This aims to address price d...
'Time to cherry pick again': Porinju Veliyath says small and midcaps have bottomed & Thomas Cook is his latest buyPorinju Veliyath sees the correction in small and midcap stocks ending. He believes patient investors will find rewards. Thomas Cook India ...
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
UHM Vacation shares list at 25% discount to IPO price on BSE SME platformUHM Vacation Listing: UHM Vacation shares debuted on the BSE SME platform at a significant 25% discount to its IPO price, listing at Rs 132...
Vahh Chemicals shares list at 17% premium over IPO price on BSE SME platformVahh Chemicals Listing: Vahh Chemicals debuted on the BSE SME platform with a nearly 17% premium, listing at Rs 70 against its IPO price of...
Betting big on mid and smallcaps; largecaps most expensive on PEG basis, says Dinshaw IraniHelios Mutual Fund is shifting investments from large companies to mid and small companies. This move follows earnings growth trends where ...
PE investor BC Investments sells Rs 612 crore stake in Emcure Pharma; Kotak MF picks up stakePrivate equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...
Promoter sells Rs 1,024 crore worth of Ajanta Pharma shares in block deal to Kotak MF and ABSL MFA promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...
SBI in $1 billion funding for Sun Pharma’s US dealState Bank of India is set to commit up to $1 billion to fund Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co....
Q4 FY26 earnings: Metal companies lead growth, backed by robust volumes and favourable pricing trendsET Wealth presents an 8-quarter earnings assessment report of various sectors. The year-on-year net profit growth for 18 sectors is present...
These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
Ipca Laboratories among 5 stocks showing bullish RSI upswingFive Nifty500 stocks, including Leela Palaces, Eris Lifesciences, Indian Bank, Mankind Pharma, and Ipca Laboratories, showed bullish moment...